Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, single dose, and multi dose incremental phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults

Trial Profile

A randomized, double-blind, placebo-controlled, single dose, and multi dose incremental phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AC-201-Accropeutics (Primary)
  • Indications Unspecified
  • Focus Adverse reactions

Most Recent Events

  • 06 Mar 2025 New trial record
  • 08 Sep 2023 According to Accropeutics media release ,company announced that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the National Medical Products Administration (NMPA) to launch clinical phase 1 trial in China. AC-201 was approved for clinical trials by HREC in Australia in May 2023, and thePhase 1 clinical trial in Australia is currently underway.
  • 12 May 2023 According to Accropeutics media release ,company announced that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch clinical phase I trial in Australia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top